Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of IM19 CAR-T cells in relapsed or refractory CD19-positive mantle cell lymphoma
CTR20213332Phase 2Active
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Mar 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of IM19 in mantle cell lymphoma (MCL), sponsored by Immunochina Pharmaceuticals. Started Mar 2022; status: active.
02
Drugs
IM19
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20213332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213332.